An overview of new and novel pharmacotherapies for use in traumatic brain injury

Clinical and Experimental Pharmacology and Physiology

Volumn 28, Issue 11, 2001, Pages 919-921

  Vink, Robert ^a,b   Nimmo, Alan J ^a   Cernak, Ibolja ^a  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Apoptosis; Brain injury; Gender; Neurotrauma; Tachykinin; Therapy

Indexed keywords

ANTIDEPRESSANT AGENT; ANTINOCICEPTIVE AGENT; CYCLOSPORIN A; ESTROGEN; MAGNESIUM CHLORIDE; MAGNESIUM SULFATE; N METHYL DEXTRO ASPARTIC ACID; PROGESTERONE; SUBSTANCE P ANTAGONIST;

APOPTOSIS; AXONAL INJURY; BRAIN EDEMA; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN MITOCHONDRION; CELL DEATH; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG TRANSPORT; HUMAN; NEUROGENIC INFLAMMATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; SEX DIFFERENCE; TREATMENT OUTCOME;

BRAIN INJURIES; CLINICAL TRIALS; CYCLOSPORINE; GONADAL STEROID HORMONES; HUMANS; MAGNESIUM; SUBSTANCE P;

EID: 0035166211     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2001.03548.x     Document Type: Conference Paper

References (33)

1. Novel pharmacologic strategies in the treatment of experimental traumatic brain injury
2. Clinical neuroprotection trials in severe traumatic brain injury: Lessons from previous studies
3. Pharmacological strategies in CNS trauma
4. Novel pharmacologic therapies in the treatment of experimental traumatic brain injury: A review
5. Pharmacologic treatment of acute traumatic brain injury
6. Decline in intracellular free magnesium concentration is associated with irreversible tissue injury following brain trauma
7. Traumatic brain axonal injury produces sustained decline in intracellular free magnesium concentration
8. Decrease in cerebral free magnesium concentration following closed head injury and effects of VA-045 in rats
9. Magnetic resonance spectroscopy of diffuse brain trauma in the pig
10. 31P magnetic resonance spectroscopy and behavioural studies
11. Optimisation of magnesium therapy following severe diffuse axonal brain injury in rats
12. Magnesium and ketamine attenuate cognitive dysfunction following experimental brain injury
13. Postinjury treatment with magnesium chloride attenuates cortical damage after traumatic brain injury in rats
14. Delayed therapy with magnesium up to 24 h following traumatic brain injury improves motor outcome
15. 2+
16. 2+
17. Changes in DNA fragmentation factor (DFF) following experimental brain trauma in the rat: Effect of posttraumatic magnesium treatment
18. Postinjury magnesium treatment attenuates traumatic brain injury-induced cortical induction of p53 mRNA in rats
19. 2+ of NMDA responses in spinal cord neurons
20. Alcohol-induced vascular damage of brain is ameliorated by administration of magnesium
21. The giant channel of the inner mitochondrial membrane is inhibited by cyclosporin A
22. Limitations of cyclosporin A inhibition of the permeability transition in CNS mitochondria
23. Cyclosporin A protects against ischaemia-reperfusion injury in the brain
24. Cycolsporin A dramatically ameliorates CA1 hippocampal damage following transient forebrain ischemia in the rat
25. Cyclosporin A significantly ameliorates cortical damage following experimental traumatic brain injury in rodents
26. Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury
27. Cyclosporin A is a substance P (tachykinin NK1) receptor antagonist
28. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists
29. Neurokinin-1 receptor antagonist SR140333: A novel type of drug to treat ischemia
30. Inhibition of neurogenic inflammation improves motor and cognitive outcome following diffuse traumatic brain injury
31. Gender differences in acute CNS trauma and stroke: Neuroprotective effects of estrogen and progesterone
32. Estrogen improves biochemical and neurologic outcome following traumatic brain injury in male rats but not in females